GET DAILY SIGNALSCuriosityStream (CURI): A Focused Approach to Factual Content and Expanding Licensing
Key Takeaways
- CURI is the stock ticker for CuriosityStream Inc., a factual-entertainment streaming and media company founded in 2015 by Discovery Channel founder John S. Hendricks.
- The company specializes in documentary and non-fiction programming across science, nature, history, technology, society, and lifestyle.
- Revenue comes primarily from two streams: a direct subscription business and a fast-growing content-licensing business that includes selling rights-cleared content to artificial intelligence (AI) developers.
- CuriosityStream is headquartered in Silver Spring, Maryland, and its service is available in more than 175 countries.
- As a small-cap media company, CURI carries elevated risks tied to subscriber churn, competition, and licensing concentration.
Company Background
CuriosityStream Inc. (CURI) operates as a media and entertainment firm centered on premium factual programming. Instead of chasing broad entertainment audiences, it concentrates on documentaries, series, and short-form videos covering science, nature, history, technology, society, and lifestyle. I follow the stock because it carves out a specific niche in the streaming space, and its model has shifted from subscriptions alone to include meaningful content-licensing income, some of it tied to AI model training.
Leadership and Operations
CuriosityStream was started in 2015 by John S. Hendricks, who earlier built Discovery Channel and chaired Discovery Communications. Clint Stinchcomb is the current chief executive, while Hendricks stays on as chairman. The company is based in Silver Spring, Maryland, and went public on Nasdaq in 2020 via a SPAC merger.
Its main offering is a subscription video-on-demand service with thousands of documentary titles. It also runs a linear channel called the Curiosity Channel and offers free ad-supported options. The "Smart Bundle" adds access to services such as Tastemade, Kidstream, SommTV, and Curiosity University.
Revenue comes from several areas. The direct business includes direct-to-consumer subscriptions through its site and apps, plus partner distribution on platforms like Amazon Prime Video Channels, Apple, Roku, Sling TV, YouTube TV, and providers such as Comcast, Cox, and Dish. Content licensing covers sales of titles to other media firms and, more recently, rights-cleared material and data to AI developers. A smaller bundled distribution segment handles affiliate deals with broadband and wireless partners.
In fiscal 2025, total revenue reached $71.7 million, a 40% increase from the previous year. The direct business accounted for $33.6 million and content licensing for $33.2 million, showing how licensing has grown to match the scale of subscriptions.
Investor Appeal
From what I see, CURI's long-term draw lies in its clear positioning rather than near-term price action. Its emphasis on factual and educational material sets it apart from general entertainment platforms, supporting a recognizable brand and dedicated viewers. The founder-led background and ties in the documentary world aid its content efforts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The standout growth factor lately is content licensing. Management has steered the company toward supplying rights-cleared material to media outlets and AI developers needing quality video and data for training. This shift has boosted revenue, aided profitability, and supported cash flow. The firm also began paying a quarterly dividend, which stands out for a small-cap streamer and points to a focus on shareholder returns.
Broad distribution through major platforms and pay-TV providers helps reach users without full direct-acquisition costs.
Risks to Consider
Several factors deserve attention with CURI. Direct subscriber numbers have fallen, so growth now leans more on third-party partners and licensing. Concentration among licensing customers raises questions, and AI-related deals can vary quarter to quarter.
Competition remains strong from much larger streaming services with bigger resources and libraries. Economic conditions, spending patterns, and media consumption shifts can influence demand. As a small-cap name, the stock may show more volatility and thinner liquidity than larger peers.
The move into licensing, particularly AI deals, is still relatively new, so the staying power and pricing of those arrangements have yet to be tested across a full cycle.
Using Tickeron’s AI Screener
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter stocks and ETFs by technical indicators, fundamentals, trends, and custom criteria. It helps surface ideas that align with specific strategies without sifting through thousands of names manually. The platform’s AI-generated signals and pattern tools make it straightforward to compare opportunities across industries and refine a watchlist efficiently.
Conclusion
CuriosityStream holds a distinct spot in media as a pure-play factual streaming company with founder roots and an expanding licensing side. Its move from a subscription-heavy model to one serving both consumers and institutional buyers of content and data offers a useful example of how niche platforms adapt. While its size, subscriber patterns, and competitive environment call for caution, CURI stays relevant for those tracking digital media trends and the growing link between content and AI.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
CURI's RSI Oscillator entering oversold zone
The RSI Indicator for CURI moved into overbought territory on November 11, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CURI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CURI as a result. In 68 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for CURI turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
CURI moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CURI crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CURI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. CURI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.592) is normal, around the industry mean (3.429). CURI's P/E Ratio (1606.560) is considerably higher than the industry average of (112.313). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.298). CURI has a moderately high Dividend Yield (0.135) as compared to the industry average of (0.045). P/S Ratio (2.156) is also within normal values, averaging (8.232).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CURI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is a call option?
Should I Trust an Article Such as “What Are The Best 10 Stocks For The Next 10 Years?”
What has been the historical performance of IPOs?
What is a Unicorn in the World of Startups and Why Does It Matter?
AI Trading Strategy Captures strong performance During FOMC Market Swings (SPY)
General Information
a blank check company which, engages in effectuating a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Broadcasting
Advertisement